DE69419958D1 - Verwendung des Keratinozyten Wachstumsfaktors (KGF) für die Herstellung von Arzneimitteln - Google Patents
Verwendung des Keratinozyten Wachstumsfaktors (KGF) für die Herstellung von ArzneimittelnInfo
- Publication number
- DE69419958D1 DE69419958D1 DE69419958T DE69419958T DE69419958D1 DE 69419958 D1 DE69419958 D1 DE 69419958D1 DE 69419958 T DE69419958 T DE 69419958T DE 69419958 T DE69419958 T DE 69419958T DE 69419958 D1 DE69419958 D1 DE 69419958D1
- Authority
- DE
- Germany
- Prior art keywords
- kgf
- drugs
- manufacture
- growth factor
- keratinocyte growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 title 2
- 229940079593 drug Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000001727 in vivo Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 210000002510 keratinocyte Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4074293A | 1993-03-26 | 1993-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69419958D1 true DE69419958D1 (de) | 1999-09-16 |
DE69419958T2 DE69419958T2 (de) | 2000-04-20 |
Family
ID=21912689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69419958T Expired - Lifetime DE69419958T2 (de) | 1993-03-26 | 1994-03-25 | Verwendung des Keratinozyten Wachstumsfaktors (KGF) für die Herstellung von Arzneimitteln |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0619370B1 (de) |
JP (1) | JP3578761B2 (de) |
KR (1) | KR100390340B1 (de) |
CN (1) | CN1064710C (de) |
AT (1) | ATE183233T1 (de) |
AU (1) | AU707340B2 (de) |
CA (1) | CA2159109C (de) |
CZ (1) | CZ285996B6 (de) |
DE (1) | DE69419958T2 (de) |
DK (1) | DK0619370T3 (de) |
ES (1) | ES2136673T3 (de) |
FI (1) | FI954541A (de) |
GR (1) | GR3031509T3 (de) |
HU (1) | HU220641B1 (de) |
IL (4) | IL137581A (de) |
NO (1) | NO953781L (de) |
NZ (1) | NZ263967A (de) |
RU (1) | RU2146148C1 (de) |
SG (1) | SG49841A1 (de) |
SI (1) | SI0619370T1 (de) |
SK (1) | SK281674B6 (de) |
UA (1) | UA46706C2 (de) |
WO (1) | WO1994023032A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN271295A0 (en) * | 1995-05-02 | 1995-05-25 | Gropep Pty Ltd | Method of treatment |
WO1996011949A2 (en) * | 1994-10-13 | 1996-04-25 | Amgen Inc. | Analogs of keratinocyte growth factor |
US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
EP0815115B1 (de) * | 1995-02-14 | 2003-05-28 | Human Genome Sciences, Inc. | Keratinozyten-wachstumsfaktor 2 |
US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
ES2224178T3 (es) * | 1995-10-11 | 2005-03-01 | Chiron Corporation | Cobinacion de pdgf, kgf,igf e igfbp para la cicatrizacion de heridas. |
GB9619660D0 (en) * | 1996-09-20 | 1996-11-06 | Scient Hospital Suppl Int Ltd | Prevention of gastrointestinal damage |
US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
AU725509B2 (en) * | 1996-10-15 | 2000-10-12 | Biovitrum Ab (Publ) | Uses of keratinocyte growth factor-2 |
SI0941110T1 (en) * | 1996-10-15 | 2004-06-30 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
US6228839B1 (en) * | 1997-12-19 | 2001-05-08 | Emory University | Use of keratinocyte growth factor to improve oxidative status |
US6238888B1 (en) | 1997-12-22 | 2001-05-29 | Human Genone Sciences, Inc. | Keratinocyte growth factor-2 formulations |
US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
EP1054900A4 (de) | 1998-02-13 | 2004-12-22 | Human Genome Sciences Inc | Therapeutische verwendungen des keratinozten wachstumsfaktors-2 |
US6335317B1 (en) | 1998-04-10 | 2002-01-01 | Emory University | Use of gut-trophic growth factors to improve oxidative status |
ES2240430T3 (es) * | 2000-03-20 | 2005-10-16 | Pfizer Products Inc. | Tratamiento combinado con factor de crecimiento de queratinocitos e inhibidor del factor de crecimiento epidermico. |
CA2437270A1 (en) * | 2001-02-06 | 2002-08-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
CA2580107A1 (en) * | 2004-09-13 | 2006-03-23 | University Of Southampton | Growth factor treatment for asthma |
CN101822821B (zh) * | 2010-04-27 | 2013-01-23 | 复旦大学附属中山医院 | 角质细胞生长因子-2在制备防治肺损伤的药物中的应用 |
CN104707164B (zh) * | 2015-03-31 | 2017-01-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种复合壳聚糖水凝胶敷料及其制备方法和应用 |
CN106226511B (zh) * | 2016-07-28 | 2018-04-06 | 苏州金盟生物技术有限公司 | 一种重组人角质细胞生长因子生物学活性检测方法 |
CN107753932A (zh) * | 2016-08-22 | 2018-03-06 | 中国辐射防护研究院 | Kgf在制备治疗或预防放射性肠炎药物中的用途 |
WO2020111047A1 (ja) | 2018-11-27 | 2020-06-04 | 株式会社海月研究所 | 頭皮頭髪用組成物 |
KR20210114646A (ko) * | 2020-03-11 | 2021-09-24 | (주)메디코스바이오텍 | 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1016716A3 (de) * | 1989-01-31 | 2000-07-12 | RUBIN, Jeffrey S | Dns kodierend für einen für Epithelzellen spezifischen Wachstumsfaktor |
JPH04224522A (ja) * | 1990-04-27 | 1992-08-13 | Merck & Co Inc | 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法 |
WO1992014480A1 (en) * | 1991-02-22 | 1992-09-03 | Amgen Inc. | Use of gm-csf and g-csf to promote accelerated wound healing |
-
1994
- 1994-03-24 UA UA95104698A patent/UA46706C2/uk unknown
- 1994-03-24 KR KR1019950704154A patent/KR100390340B1/ko not_active IP Right Cessation
- 1994-03-24 SK SK1185-95A patent/SK281674B6/sk not_active IP Right Cessation
- 1994-03-24 CN CN94192037A patent/CN1064710C/zh not_active Expired - Lifetime
- 1994-03-24 CZ CZ952482A patent/CZ285996B6/cs not_active IP Right Cessation
- 1994-03-24 NZ NZ263967A patent/NZ263967A/en not_active IP Right Cessation
- 1994-03-24 CA CA002159109A patent/CA2159109C/en not_active Expired - Lifetime
- 1994-03-24 JP JP52218894A patent/JP3578761B2/ja not_active Expired - Lifetime
- 1994-03-24 RU RU95117959A patent/RU2146148C1/ru active
- 1994-03-24 IL IL137581A patent/IL137581A/en not_active IP Right Cessation
- 1994-03-24 AU AU65243/94A patent/AU707340B2/en not_active Expired
- 1994-03-24 IL IL10912294A patent/IL109122A/en not_active IP Right Cessation
- 1994-03-24 WO PCT/US1994/003208 patent/WO1994023032A1/en active IP Right Grant
- 1994-03-24 HU HU9502800A patent/HU220641B1/hu unknown
- 1994-03-25 DE DE69419958T patent/DE69419958T2/de not_active Expired - Lifetime
- 1994-03-25 EP EP94104804A patent/EP0619370B1/de not_active Expired - Lifetime
- 1994-03-25 SG SG1996007376A patent/SG49841A1/en unknown
- 1994-03-25 ES ES94104804T patent/ES2136673T3/es not_active Expired - Lifetime
- 1994-03-25 DK DK94104804T patent/DK0619370T3/da active
- 1994-03-25 SI SI9430265T patent/SI0619370T1/xx unknown
- 1994-03-25 AT AT94104804T patent/ATE183233T1/de active
-
1995
- 1995-09-25 FI FI954541A patent/FI954541A/fi unknown
- 1995-09-25 NO NO953781A patent/NO953781L/no not_active Application Discontinuation
-
1999
- 1999-10-13 GR GR990402604T patent/GR3031509T3/el unknown
-
2000
- 2000-07-30 IL IL13758100A patent/IL137581A0/xx unknown
-
2004
- 2004-04-22 IL IL16156804A patent/IL161568A0/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69419958D1 (de) | Verwendung des Keratinozyten Wachstumsfaktors (KGF) für die Herstellung von Arzneimitteln | |
Khouri et al. | The effect of basic fibroblast growth factor on the neovascularisation process: skin flap survival and staged flap transfers | |
ATE308545T1 (de) | Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
DE69835680D1 (de) | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten | |
FR2644066B1 (fr) | Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques | |
DE69738336D1 (de) | Verwendung von keratinocyte growth factor-2 | |
DE69328527D1 (de) | Carboxypeptidase-ähnliches Protein aus Knochen und Verfahren zur dessen Herstellung | |
ATE513900T1 (de) | Herstellung und verwendung von humanen cd124 und cd116 positiven tumorzelllinien zur herstellung von allogenen oder semi-allogenen immuntherapeutika | |
DE69334087D1 (de) | Arzneimittelzusammensetzung enthaltend TCF-II | |
Jorgensen et al. | Evaluation of the wound healing potential in human beings from the subcutaneous insertion of expanded polytetrafluoroethylene tubes: a methodologic study | |
AU1200488A (en) | Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci | |
DE69837380D1 (de) | Biologisches material zur behandlung eines säugetieres durch transfer einesfür einen antikörper kodierendes gen und eine pharmazeutische zusammensetzungdie diese enthält | |
RU2090155C1 (ru) | Способ пластики хрящевого дефекта спинки носа | |
RU1804797C (ru) | Способ эндоссальной имплантации | |
RU2210352C1 (ru) | Композиция для лечения воспалительных заболеваний пародонта на основе клеточных культур | |
Klein | Modulation of cutaneous wound healing mechanisms to affect characteristics of healing | |
Filippi | Ozone Research Repository | |
Huizinga | Trauma and orthopaedic infections. | |
Wagner Jr | voluntarily to prolong inspiration or produce expiratory | |
TH41485A (th) | วิธีสำหรับรักษาภาวะการแข็งตัวของเลือดเกินหรือภาวะการพร่องโปรตีนชีที่ได้รับภายหลัง | |
WO1999042132A1 (en) | Use of anti-cd44 monoclonal antibody to enhance wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: BIOVITRUM AB (PUBL), STOCKHOLM, SE |